Active Ingredient History
Dalteparin is a low molecular weight heparin. It is marketed as Fragmin. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism to reduce the risk of a stroke or heart attack. Dalteparin acts by potentiating the activity of antithrombin III, inhibiting formation of both Factor Xa and thrombin. It is normally administered by self-injection. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Abortion, Habitual (Phase 3)
Anemia, Sickle Cell (Phase 2)
Angina, Unstable (Phase 4)
Anticoagulants (Phase 4)
Arterial Occlusive Diseases (Phase 3)
Atrial Fibrillation (Phase 3)
Brain Injuries, Traumatic (Phase 3)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 3)
Carcinoma, Hepatocellular (Phase 2)
Carcinoma, Renal Cell (Phase 1)
Colorectal Neoplasms (Phase 3)
Critical Illness (Phase 3)
Dalteparin (Phase 4)
Diabetic Foot (Phase 2/Phase 3)
Duodenal Neoplasms (Phase 2)
Embolism and Thrombosis (Phase 2)
Esophageal Neoplasms (Phase 4)
General Surgery (Phase 4)
Hemorrhage (Phase 4)
Intestinal Neoplasms (Phase 2)
Kidney Diseases (Phase 1)
Kidney Failure, Chronic (Phase 3)
Leukemia (Phase 3)
Liver Diseases (Phase 3)
Liver Neoplasms (Phase 4)
Lung Neoplasms (Phase 4)
Lymphoma (Phase 3)
Multiple Myeloma (Phase 3)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 3)
Myocardial Infarction (Phase 4)
Neoplasm Metastasis (Phase 3)
Neoplasms (Phase 4)
Nephrotic Syndrome (Phase 1/Phase 2)
Obesity (Phase 2)
Ovarian Neoplasms (Phase 2)
Pancreatic Neoplasms (Phase 4)
Postpartum Period (Phase 3)
Precancerous Conditions (Phase 3)
Pre-Eclampsia (Phase 4)
Pregnancy (Phase 3)
Pregnancy Complications (Phase 3)
Prostatic Neoplasms (Phase 3)
Pulmonary Embolism (Phase 4)
Renal Dialysis (Phase 2/Phase 3)
Renal Insufficiency (Phase 4)
Shock, Septic (Phase 2)
Stomach Neoplasms (Phase 2)
Stroke (Phase 3)
Therapeutics (Phase 4)
Thrombocytopenia (Phase 4)
Thromboembolism (Phase 4)
Thrombophilia (Phase 3)
Thrombophlebitis (Phase 4)
Thrombosis (Phase 4)
Upper Extremity (Phase 4)
Upper Extremity Deep Vein Thrombosis (Phase 4)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 3)
Venous Thromboembolism (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
